Orphan drug commercialization in Europe

Biotech team weigh up European orphan drug opportunity.

The Challenge

Our client was a US-based clinical stage biotech company developing a reformulation of a well-established orphan drug targeting a range of indications in neuro-endocrinology.

Client leadership requested Clarivate to validate key assumptions on the revenue forecast of the drug in its lead indication and provide guidance on the go-to-market model and associated costs in order to inform a go/no go decision on launch of the drug in Europe.

The client needed to understand:

• The size of the addressable patient population given epidemiology and the evolution of treatment landscape
• Pricing and access expectations, and potential price/access trade-offs
• Uptake and peak preference share given the current and future competitive landscape
• Medical, access and commercial resources required for a successful launch